Your browser is no longer supported. Please, upgrade your browser.
RGNX REGENXBIO Inc. daily Stock Chart
RGNX [NASD]
REGENXBIO Inc.
Index- P/E- EPS (ttm)-2.78 Insider Own0.60% Shs Outstand37.10M Perf Week-2.36%
Market Cap1.41B Forward P/E- EPS next Y-2.00 Insider Trans-43.65% Shs Float31.17M Perf Month1.33%
Income-102.50M PEG- EPS next Q-0.94 Inst Own91.10% Short Float13.76% Perf Quarter10.45%
Sales52.00M P/S27.10 EPS this Y-194.70% Inst Trans4.45% Short Ratio10.48 Perf Half Y-13.49%
Book/sh11.32 P/B3.29 EPS next Y29.80% ROA-20.50% Target Price- Perf Year-19.06%
Cash/sh7.37 P/C5.05 EPS next 5Y2.00% ROE-22.40% 52W Range20.03 - 54.97 Perf YTD-9.20%
Dividend- P/FCF- EPS past 5Y-68.50% ROI-32.50% 52W High-32.33% Beta1.07
Dividend %- Quick Ratio10.60 Sales past 5Y41.90% Gross Margin77.60% 52W Low85.72% ATR1.91
Employees257 Current Ratio10.60 Sales Q/Q1895.90% Oper. Margin- RSI (14)48.03 Volatility5.45% 5.32%
OptionableYes Debt/Eq0.00 EPS Q/Q-21.80% Profit Margin- Rel Volume0.43 Prev Close38.36
ShortableYes LT Debt/Eq0.00 EarningsMay 07 AMC Payout- Avg Volume409.26K Price37.20
Recom2.10 SMA200.12% SMA50-3.35% SMA200-5.35% Volume175,804 Change-3.02%
Jun-25-20Resumed BofA/Merrill Buy $9
Jun-25-20Resumed BofA/Merrill Buy $60
May-13-20Initiated RBC Capital Mkts Sector Perform $42
Aug-20-19Upgrade SVB Leerink Underperform → Mkt Perform $38 → $37
Jun-18-19Reiterated Chardan Capital Markets Buy $145 → $150
Jun-14-19Resumed Raymond James Outperform
Jun-05-19Reiterated Chardan Capital Markets Buy $127.50 → $145
Feb-25-19Upgrade Evercore ISI In-line → Outperform
Feb-05-19Upgrade Raymond James Outperform → Strong Buy $94
Dec-17-18Reiterated Chardan Capital Markets Buy $127.50
Nov-08-18Reiterated BofA/Merrill Neutral $76 → $84
Aug-08-18Reiterated Chardan Capital Markets Buy $130 → $127.50
Jul-23-18Downgrade BofA/Merrill Buy → Neutral
Jul-10-18Reiterated Chardan Capital Markets Buy $90 → $130
May-09-18Reiterated Barclays Overweight $38 → $48
Apr-09-18Reiterated Chardan Capital Markets Buy $85 → $90
Mar-12-18Downgrade Evercore ISI Outperform → In-line
Feb-13-18Initiated Mizuho Neutral $28
Nov-09-17Resumed Morgan Stanley Overweight $34
Nov-09-17Reiterated Chardan Capital Markets Buy $75 → $85
Jul-08-20 07:05AM  
Jun-23-20 07:42PM  
Jun-10-20 07:30AM  
Jun-04-20 08:49AM  
May-12-20 09:06AM  
May-10-20 03:19PM  
May-07-20 08:31PM  
Apr-30-20 04:31PM  
Apr-28-20 05:38PM  
12:33PM  
Apr-27-20 01:55PM  
Apr-23-20 09:12AM  
Apr-22-20 06:30AM  
Mar-31-20 04:05PM  
Mar-13-20 10:02AM  
09:34AM  
Mar-09-20 07:00AM  
02:26AM  
Mar-02-20 08:45AM  
Feb-26-20 07:15PM  
04:05PM  
02:34PM  
Feb-25-20 08:10AM  
Feb-19-20 12:31PM  
Jan-29-20 07:00AM  
Jan-28-20 01:12PM  
Jan-10-20 10:08AM  
Jan-09-20 08:30PM  
07:00AM  
Dec-19-19 04:22PM  
Dec-18-19 07:41AM  
Dec-16-19 09:30AM  
Dec-11-19 03:27PM  
02:07PM  
Dec-04-19 05:00AM  
Nov-06-19 04:15PM  
Nov-05-19 06:25PM  
04:05PM  
Nov-02-19 12:00PM  
Oct-31-19 04:30AM  
Oct-30-19 07:05AM  
Oct-29-19 07:00AM  
Oct-25-19 12:49PM  
09:36AM  
Oct-17-19 07:00AM  
Oct-15-19 02:48PM  
10:57AM  
Oct-11-19 07:15PM  
Oct-10-19 10:11AM  
Oct-06-19 05:15PM  
Oct-02-19 08:31AM  
Oct-01-19 01:43PM  
Sep-30-19 07:00AM  
Sep-19-19 08:29AM  
Sep-13-19 08:44AM  
Sep-09-19 12:58PM  
Sep-04-19 09:42AM  
07:00AM  
Aug-28-19 04:05PM  
01:31PM  
Aug-27-19 07:00AM  
Aug-23-19 07:36AM  
Aug-21-19 07:15PM  
Aug-12-19 04:33AM  
Aug-09-19 10:14AM  
Aug-07-19 06:15PM  
04:05PM  
Aug-06-19 02:20PM  
Jul-31-19 07:07AM  
Jul-30-19 04:05PM  
Jul-24-19 04:10PM  
04:05PM  
Jul-23-19 06:15PM  
Jul-02-19 08:41AM  
Jun-19-19 09:07PM  
Jun-11-19 07:00AM  
Jun-03-19 02:32PM  
May-28-19 01:47PM  
11:25AM  
May-24-19 07:46PM  
01:14PM  
May-15-19 07:00AM  
May-08-19 07:00AM  
May-07-19 09:24PM  
06:36PM  
04:05PM  
May-02-19 12:40PM  
Apr-30-19 07:00AM  
Apr-22-19 04:15PM  
Apr-19-19 02:48PM  
01:22PM  
Apr-17-19 07:00AM  
Apr-15-19 04:05PM  
Apr-08-19 09:45AM  
Apr-03-19 08:16AM  
Mar-26-19 07:15AM  
Mar-10-19 10:36AM  
Mar-08-19 10:40AM  
Mar-06-19 07:00AM  
Mar-05-19 08:44AM  
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's lead product candidate is RGX-314, which is in Phase I/IIa clinical trial for the treatment of wet age-related macular degeneration. It is also developing RGX-121 that is in Phase I/II clinical trial to treat mucopolysaccharidosis type II; RGX-111, which is in Phase I clinical trial for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late infantile neuronal ceroid lipofuscinosis type II disease; and RGX-501, which is in Phase I/II clinical trials to treat homozygous familial hypercholesterolemia. REGENXBIO Inc. also licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies; and has a collaboration and license agreement with Neurimmune AG to develop vectorized antibodies for the treatment of neurodegenerative diseases. The company was formerly known as ReGenX Biosciences, LLC and changed its name to REGENXBIO Inc. in September 2014. REGENXBIO Inc. was founded in 2008 and is headquartered in Rockville, Maryland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Vasista VittalChief Financial OfficerMay 11Option Exercise13.095006,545207,215May 12 04:16 PM
Vasista VittalChief Financial OfficerMay 11Sale40.0050020,000206,715May 12 04:16 PM
Vasista VittalChief Financial OfficerMay 08Option Exercise13.092,50032,725213,715May 12 04:16 PM
Vasista VittalChief Financial OfficerMay 08Sale40.187,000281,260206,715May 12 04:16 PM
Vasista VittalChief Financial OfficerApr 24Option Exercise13.093,00039,270223,215Apr 27 04:30 PM
Vasista VittalChief Financial OfficerApr 24Sale40.1112,000481,320211,215Apr 27 04:30 PM
Vasista VittalChief Financial OfficerApr 23Option Exercise13.093,00039,270223,215Apr 27 04:30 PM
Vasista VittalChief Financial OfficerApr 23Sale40.003,000120,000220,215Apr 27 04:30 PM
Vasista VittalChief Financial OfficerMar 31Option Exercise0.8510,0008,500220,215Apr 02 04:22 PM
Simpson CurranSVP, Product Development & CTOFeb 11Option Exercise22.006,633145,92616,512Feb 12 04:27 PM
Simpson CurranSVP, Product Development & CTOFeb 11Sale50.4912,564634,4113,948Feb 12 04:27 PM
HAYDEN DONALD J JRDirectorFeb 10Option Exercise0.8524,80021,08024,800Feb 12 04:22 PM
Vasista VittalChief Financial OfficerFeb 10Option Exercise13.093,00039,270225,021Feb 12 04:24 PM
Simpson CurranSVP, Product Development & CTOFeb 10Option Exercise27.1031,660858,09854,308Feb 12 04:27 PM
Simpson CurranSVP, Product Development & CTOFeb 10Sale50.2244,4292,231,2249,879Feb 12 04:27 PM
Vasista VittalChief Financial OfficerFeb 10Sale50.0714,806741,352210,215Feb 12 04:24 PM
HAYDEN DONALD J JRDirectorFeb 10Sale50.1124,8001,242,7280Feb 12 04:22 PM
Simpson CurranSVP, Product Development & CTOFeb 05Option Exercise18.085,13792,88628,285Feb 07 04:23 PM
HAYDEN DONALD J JRDirectorFeb 05Option Exercise0.852,0001,7002,000Feb 07 04:19 PM
Simpson CurranSVP, Product Development & CTOFeb 05Sale50.005,637281,85022,648Feb 07 04:23 PM
Vasista VittalChief Financial OfficerFeb 05Sale50.0030015,000222,021Feb 07 04:21 PM
HAYDEN DONALD J JRDirectorFeb 05Sale50.002,000100,0000Feb 07 04:19 PM
HAYDEN DONALD J JRDirectorJan 17Option Exercise0.853,2002,7203,200Jan 21 04:16 PM
Simpson CurranSVP, Product Development & CTOJan 17Option Exercise23.365,122119,66929,070Jan 21 04:18 PM
Vasista VittalChief Financial OfficerJan 17Sale50.002,394119,700222,321Jan 21 04:17 PM
Simpson CurranSVP, Product Development & CTOJan 17Sale50.005,922296,10023,148Jan 21 04:18 PM
HAYDEN DONALD J JRDirectorJan 17Sale50.013,200160,0320Jan 21 04:16 PM
HAYDEN DONALD J JRDirectorJan 14Option Exercise0.8530,00025,50030,000Jan 16 04:18 PM
HAYDEN DONALD J JRDirectorJan 14Sale45.6030,0001,368,0000Jan 16 04:18 PM
Vasista VittalChief Financial OfficerJan 08Option Exercise13.093,00039,270232,215Jan 10 04:20 PM
Vasista VittalChief Financial OfficerJan 08Sale41.757,500313,152224,715Jan 10 04:20 PM
Simpson CurranSVP, Product Development & CTODec 09Sale43.7415,552680,24823,948Dec 11 04:24 PM
Mills Kenneth T.President and CEOSep 19Option Exercise0.855,0004,250251,000Sep 23 04:12 PM
Mills Kenneth T.President and CEOSep 19Sale39.7510,000397,497241,000Sep 23 04:12 PM
Christmas Patrick J.SVP, General CounselSep 12Option Exercise12.105,00060,5008,058Sep 16 04:24 PM
Christmas Patrick J.SVP, General CounselSep 12Sale42.005,486230,4122,572Sep 16 04:24 PM
Mills Kenneth T.President and CEOAug 19Option Exercise0.8515,00012,750261,000Aug 21 04:17 PM
Mills Kenneth T.President and CEOAug 19Sale37.5515,000563,243246,000Aug 21 04:17 PM
Mills Kenneth T.President and CEOJul 19Option Exercise0.8515,00012,750261,000Jul 23 04:33 PM
Christmas Patrick J.SVP, General CounselJul 19Option Exercise19.504,90095,5507,958Jul 22 04:29 PM
Christmas Patrick J.SVP, General CounselJul 19Sale50.034,900245,1473,058Jul 22 04:29 PM
Mills Kenneth T.President and CEOJul 19Sale49.4915,000742,311246,000Jul 23 04:33 PM
Christmas Patrick J.SVP, General CounselJul 18Option Exercise19.501001,9503,158Jul 22 04:29 PM
Christmas Patrick J.SVP, General CounselJul 18Sale50.001005,0003,058Jul 22 04:29 PM